Introduction {#sec1}
============

The current pandemic associated with the coronavirus disease 2019 (COVID-19) has conferred an unprecedented stress on the US healthcare system. To mitigate the risk of iatrogenic infection and facilitate rationing of personal protective equipment (PPE), ventilators, and hospital beds, a variety of stakeholders including policymakers, payers, and professional societies issued guidelines for postponing elective procedures. In electrophysiology (EP), the Heart Rhythm Society (HRS) COVID-19 task force specifically recommended postponing left atrial appendage occlusion, ablation in clinically stable patients, and many CIED implants.[@bib1] Following the CT governor's declaration of a Public Health Emergency on March 10, Yale New Haven Hospital (YNHH) leadership enacted its Disaster plan including a decision to halt elective procedures on March 16. The COVID-19 inpatient census at YNHH rose to a peak of 450 cases in mid-April before gradually declining again in early May. During this period, emergent cardiac EP procedures continued, including pacemaker placement for severe bradycardia, generator replacement for those cardiovascular implantable electronic devices (CIED) nearing end of service, cardioversion for severely symptomatic atrial arrhythmias refractory to rate control, ventricular tachycardia ablation for refractory VT, and device extraction for infected CIEDs. A number of measures were instituted to protect patients who did require emergent procedures, including increasing use of masking/ other PPE, and pre-procedure testing, facilitating appropriate cohorting and patient-flow, as well as protocols and education regarding their use. ([Figure](#fig1){ref-type="fig"} )FigureTimeline of Pandemic Response and Infection-Control Measures

A fluctuating landscape requires a dynamic assessment of the risks and benefits of delaying routine healthcare. In many areas, hospitalization rates for COVID-19 are decreasing, and patients who have postponed nonemergent healthcare continue to accrue. In addition, there has been increasing recognition of morbidity and mortality associated with delays in cardiac care, including arrhythmia procedures such as biventricular ICD implantation for those with advanced heart failure and ablation for those with severe symptoms from atrial fibrillation or atrial flutter. These considerations, along with increased testing and PPE resources, have led policymakers, health system administrators, and physicians in many areas to reopen facilities for nonemergent care.

However, the COVID-19 exposure risk in this setting remains unquantified, with varying reports of in-hospital transmission among hospitalized patients.[@bib2].[@bib3] Anecdotally within our community patients have continued to express hesitancy to proceed with elective procedures, and accounts from the lay press suggest similar sentiments nationally.[@bib4] As part of a quality initiative, we performed systematic follow up after discharge to determine rates of COVID-19 infection among patients who underwent EP procedures during the current COVID era.

Methods {#sec2}
=======

Patients undergoing procedures in the Cardiac EP Laboratories at Yale New Haven Hospital between 3/16/2020 and 5/15/2020 were contacted by telephone for follow-up. Patients were asked in a structured interview format about any post-procedure testing for COVID-19 and presence and timeframe of any symptoms, in themselves or anyone in their household or family, including fever, cough, dyspnea, or chest pain, or hospitalization since the procedure. Patients were included if at least 14 days had elapsed since the procedure date to account for the maximal reported incubation period of the COVID-19 virus.[@bib5] Chart review was performed for patients who were not reached by telephone; all had documented telehealth visits after the 14-day post-procedure interval, including symptom data from the patient history and review of systems. During this time, 157 patients underwent procedures in the EP lab. Patients were excluded if they had tested positive for COVID19 prior to the procedure (N=3) or had been admitted for more than three days prior to the EP procedure, (N=30) to avoid detecting cases less likely primarily associated with the EP procedure, leaving 124 who were included in this analysis. These presented from the outpatient (n=77), emergency (n=11), and inpatient (n=36) settings. Routine pre-procedure testing began on April 11, as indicated in the figure. This project adhered to the guidelines set forth by the Office of Human Research Protection that is supported by U.S. Department of Health & Human Services. The project met Yale IRB criteria for quality improvement and thus consent was not required and the project was not reviewed under Yale policy.

Results {#sec3}
=======

124 patients met inclusion and exclusion criteria and were contacted for follow-up. Data were obtained by telephone for 117 patients (94%) and chart review for the remainder. The population was 67% male with mean age of 69 (standard deviation \[SD\]) 14 years. Procedures included CIED implants (n=56), or revisions (n=22), EP studies/ablations (n=19), and cardioversions (n=27). Clinical, hospitalization, and procedure-related characteristics are shown in the [Table](#tbl1){ref-type="table"} .TableCharacteristics of patients undergoing procedures in the electrophysiology laboratoryPatient characteristicsOutpatient---same day discharge (n = 43)Outpatient---same day admission (n = 40)Previously admitted (n = 41)Age (y)67 ± 1668 ± 1273 ± 13Male33 (77%)27 (68%)24 (59%)Temperature (°F)97.5 ± 0.697.4 ± 0.597.6 ± 0.6COVID tested preprocedure22 (51%)15 (38%)23 (56%)Length of stay (days)---1.3 ± 0.94.4 ± 4.1ICU admission03 (8%)7 (17%)TEE with procedure4 (9%)3 (8%)8 (20%)Intubated for procedure2 (4%)12 (30%)7 (17%)[^1][^2]

There were two deaths during the follow-up interval: one 94-year old patient was admitted emergently with complete heart block and heart failure that failed to improve with pacing and ultimately died during the index admission. This patient tested negative for COVID on the date of death. The second patient was a long-term care facility resident with death occurring \> 60 days after an ICD generator change.

Of the remaining patients, 7 (6%) described one or more of the symptoms assessed. 3 of these patients had COVID testing after symptom onset which was negative. Of the 4 not tested, one described chest pain diagnosed as ischemia and underwent angioplasty. Another with dyspnea was diagnosed due to pericarditis with increased atrial fibrillation burden. One patient described a 3-day isolated fever with temperature not exceeding 99^o^ F. The final patient had transient dyspnea for the first three days after atrial fibrillation ablation that self-resolved but was never tested for COVID-19. No patient described illness in a household or family member.

Discussion {#sec4}
==========

In this systematic follow-up of 124 patients who underwent cardiac EP procedures during the peak COVID period in our health system, no patients were diagnosed with COVID-19, nor were any cases suspicious for COVID19 identified, despite a high census of COVID19 at our institution. Four patients described symptoms commonly associated with COVID-19 illness and were not definitively ruled out for infection; however, two of these patients had an alternative explanation for the symptoms and in the other two, symptoms were minimal, brief, and in timeframes not suggestive of infection in the EP laboratory (ie, immediately after), thus, none met published criteria for probable COVID-19. [@bib6]

There has been interest internationally in assessing hospital-acquired infection rates for patients and healthcare providers. High reported rates of nosocomial spread in the initial stages of disease before transmission routes were fully understood remain highly publicized and frequently cited.[@bib2] More recent accounts internationally have reported much lower rates of hospital-acquired infection in the setting of escalating precautions.[@bib3] However, since the US is in the nascent stages of reopening for elective care, there have been no large systematic studies in US healthcare settings. Further, no prior studies have systematically evaluated risk of infection from exposure to the hospital setting during periods of high COVID-19 census through follow up to two weeks after possible exposure, the accepted timeframe for development of symptoms. Patient exposure rates were assessed to be low in China in the prepandemic stage,[@bib7] however this study was conducted at a time when the overall viral prevalence remained low, thereby reducing the likelihood of nosocomial exposure regardless of protective measures. For healthcare workers, data from cardiac catheterization laboratories in Italy suggest that a regimented protocol designed to minimize exposure resulted in lower rates of infection compared to units without these protocols in a prospective study.[@bib3] Data from China also showed a low rate of nosocomial spread after implementation of early isolation and expanded testing.[@bib8] However, these results are not necessarily generalizable to patients, who do not benefit from personally fitted PPE supplied to healthcare providers in these studies and who are undergoing procedures which may increase their vulnerability such as intubation and sedation. Furthermore, in an era of fluctuating availability of testing and PPE, results from highly protocolized studies may not offer a realistic profile of the infectious risk in a more fluid setting. Our systematic followup of all patients for two weeks after discharge, offers a pragmatic view of procedural safety that is generalizable to a wider range of infection-prevention strategies.

These procedures spanned a secular trend of increasing precautionary measures implemented to reduce the risk of COVID-19 transmission. Increases in local PPE supply and testing availability along with advances in community awareness of high-risk aerosolizing procedures have led to more rigorous safety protocols evolving throughout the follow-up interval, as shown in the Figure. The effectiveness of specific interventions for infection-prevention cannot be determined. Whether rates are similarly low for other interventional procedures, or are applicable to different hospital systems, cannot be determined. However, the HRS has recently published further recommendations for minimizing risk to patients and staff, very similar to those we had instituted, [@bib9] as have other groups,[@bib10] ^,^ [@bib11] suggesting our results may be generalizable to other procedures and systems following these or similar guidelines. Hospital systems should perform quality analyses to determine the efficacy of their viral- infection-prevention measures as is routinely done for infection prevention in general.

We did not query less specific symptoms such as headache or myalgia, and cannot exclude the possibility of transmission resulting in mild or no symptoms. It is a limitation of this report, that routine testing was not performed pre-procedure until several weeks into the pandemic, and not performed routinely post-procedure.. This report describe an early experience, during a time period when testing was not easily available and not routinely used even if symptomatic. Similar to the measures taken at our hospital, community precautions also evolved during this time period, with initial limitations on crowd size and closing certain businesses on March 16^th^ then continuing to evolve. We did not query in detail patients' personal exposures, and so had there been infections, it would have been difficult to confirm their source. However, as we did not see infections, this does not impact the conclusions regarding lack of transmission in the EP lab.

Conclusions: {#sec5}
============

Our findings, along with increasingly well-informed national guidelines promoting patient safety measures, should offer reassurance to patients concerned about the risks of COVID-19 transmission during emergent and elective procedures. As national guidelines seek to standardize transmission precautions, our findings may be generalizable to other types of procedures and healthcare systems employing these guidelines as well.
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[^1]: TEE: transesophageal echocardiogram. Continuous variables expressed as mean ± standard deviation.

[^2]: \*The 60 COVID tests done preprocedure were negative. An additional 3 patients with known positive tests preprocedure were excluded from analysis (see methods).
